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Salmeterol is a potent selective fl2 agonist that has a duration of action in excess of 12 hours in vitro and in vivo.8 In a four week parallel group study in 692 patients with mild to moderate asthma salmeterol increased morning and evening peak flow, reduced the variation in diurnal peak flow, reduced the requirement for additional salbutamol, and lessened symptoms by comparison with placebo. 9 This study was designed to investigate the safety and efficacy of salmeterol (50 ,ug) twice daily and salbutamol (400 ,ug) four times daily, both as dry powders, in patients with mild to moderate reversible airways obstruction over a three month period. The Daytime asthma symptom score 0 = No symptoms during the day I = Symptoms for one short period during the day 2 = Symptoms for two or more short periods during the day 3 = Symptoms for most of the day which did not affect your normal daily activities 4 = Symptoms for most of the day which did affect your normal daily activities 5 = Symptoms so severe that you could not go to work or perform normal daily activities table 1), or a diurnal variation in PEF of at least 15% on four of the last seven days of the run in period. Patients who required >20 mg prednisolone were excluded. A total of 460 patients with a clinical history of mild to moderate reversible airways obstruction and no other serious medical conditions entered the run in period and of these 388 (table 2) were randomised to receive treatment (190 received salmeterol, 198 received salbutamol). The study was performed in 47 centres in 11 countries (see acknowledgements). All patients gave informed consent. Regulatory permission was obtained from all countries where it was required and approval from the appropriate ethics committee was obtained for all centres.
STUDY MEDICATION
The study was of a randomised, double blind, double dummy, parallel group design. There was a two week run in period in which patients took either salbutamol by pressurised inhaler or a salbutamol Diskhaler when necessary for the relief of symptoms. This same rescue medication was also available during the treatment period. After the run in period, patients were randomised for three months to salmeterol (50 pg) twice daily and placebo four times daily or salbutamol (400 ,ug) four times daily and placebo twice daily. During the final nine months patients received either salmeterol (50 ,ug) twice daily or salbutamol (31) 108 (57) 7 (4) 13 (7) 27 (14) 110 (56) 61 (31) 112 (57) 11 (6) 13 (7) % in parentheses Figure 1 shows the changes in mean morning and evening PEFs over the 12 weeks of treatment. Increase in mean morning PEF was significantly higher in patients taking salmeterol than in patients taking salbutamol (p < 0 001); the mean difference was 21 I/min (95% confidence interval (95% CI) 12-31). Salmeterol also caused a significant reduction in the diurnal variation in PEF compared with salbutamol (p < 0-001); the mean variation was from 30 1/min at baseline to 11 1/min during salmeterol treatment compared with 34 1/min at baseline to 32 1/min during salbuterol treatment. Figure 2 shows the weekly median percentage of nights with no symptoms of asthma. The number of nights with no symptoms was higher during salmeterol treatment than with salbutamol treatment (p < 0001). Median values were 29% during the run in period for both groups. During treatment with salmeterol the median value increased to 100%, and with salbutamol it increased to 71%. Treatment with salmeterol was associated with significantly less use of rescue salbutamol during the day (fig 3) . FEV, increased with both salmeterol and salbutamol treatment over the 12 month treatment period (mean change for salmeterol varied from 0-23 to 0 28 1 and for salbutamol from 0 1 to 0-15 1). These changes were significantly greater for salmeterol at some but not all visits (see fig 4) . Both study drugs were well tolerated and the overall incidence and nature of adverse events in the two groups were similar. The most commonly reported adverse event was exacerbation of asthma defined as episodes of acute asthma requiring additional or increased treatment other than relief /32 agonists. Tables 3 and 4 show the number of patients with exacerbations of asthma and the frequency of exacerbations during each of the three monthly intervals for salmeterol and salbutamol respectively. The frequency of exacerbations was highest during the first three months of the study but this almost certainly reflects the greater frequency of study visits during this period. For both treatments the number of patients reporting exacerbations and the frequency of exacerbations did not increase during the last nine months of the study. This was also the case when the study population was subdivided into those not taking concomitant steroids, those taking inhaled steroids, and those taking oral steroids. Table 5 summarises the incidence of the pharmacologically predictable and most common (>5%) adverse events for the first three months. There were no significant differences between the two groups. Twenty seven patients (12 receiving salmeterol, 15 receiving salbutamol) experienced serious adverse events requiring admission to hospital. Seventeen of these events involved exacerbations of asthma, of which seven occurred in patients receiving salmeterol and 10 in patients receiving salbutamol. One patient in the salbutamol group died as a result of a myocardial infarction, which was considered to be unlikely to be related to the study drug. There were also no significant changes in haematological and biochemical indices in either group and no significant changes were noted in heart rate, systolic and diastolic blood pressure, or 12 lead electrocardiograms.
Discussion
The data presented from this large multicentre clinical trial show that compared with salbutamol (400 pg four times daily) salmeterol (50 pg twice daily) produced significantly greater improvements in lung function, including a reduction in the diurnal variation of peak flow to a normal level. Also both the requirement for bronchodilator treatment to relieve symptoms and the symptoms of asthma during the day and night were reduced. These improvements occurred during the first week of treatment and were sustained throughout the 12 weeks of detailed study with no evidence of deterioration in control of asthma. Both treatments were well tolerated with a similar low incidence of adverse events in the two groups.
The study was continued for a further nine months with the patients receiving salbutamol at a lower frequency (twice daily). This facilitated the continued use of a double dummy technique to maintain blinding. During this extension the control of asthma as assessed by exacerbation rate and lung function at the clinic was maintained. The incidence of exacerbations of asthma in both groups was higher during the first three months (almost certainly as a result of the greater frequency of clinic visits), and then declined during the next nine months. Thus there was no evidence of waning control of asthma or decline aerosol has been shown to be equivalent to salbutamol given as 400 pg of dry powder. '7 We therefore believe that this dose of salbutamol would give an acute effect roughly equal to that of salmeterol (50 pg) although the effect would not be maintained for the same length of time. The change in the dose of salbutamol from four times to twice daily after three months was to aid continued compliance. During the final nine months lung function was measured at the clinic at regular intervals and this was usually in the morning so the maintained effect of salbutamol is to be expected. Thus salmeterol given either as a dry powder or by metered dose aerosol'8 is an effective treatment for asthma over at least 12 months compared with salbutamol.
